JP2016517960A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517960A5
JP2016517960A5 JP2016506682A JP2016506682A JP2016517960A5 JP 2016517960 A5 JP2016517960 A5 JP 2016517960A5 JP 2016506682 A JP2016506682 A JP 2016506682A JP 2016506682 A JP2016506682 A JP 2016506682A JP 2016517960 A5 JP2016517960 A5 JP 2016517960A5
Authority
JP
Japan
Prior art keywords
her3
amount
her2
total
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016506682A
Other languages
English (en)
Japanese (ja)
Other versions
JP6402173B2 (ja
JP2016517960A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/033208 external-priority patent/WO2014165855A1/en
Publication of JP2016517960A publication Critical patent/JP2016517960A/ja
Publication of JP2016517960A5 publication Critical patent/JP2016517960A5/ja
Application granted granted Critical
Publication of JP6402173B2 publication Critical patent/JP6402173B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016506682A 2013-04-05 2014-04-07 Ｈｅｒ３の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法 Expired - Fee Related JP6402173B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361809083P 2013-04-05 2013-04-05
US61/809,083 2013-04-05
PCT/US2014/033208 WO2014165855A1 (en) 2013-04-05 2014-04-07 Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation

Publications (3)

Publication Number Publication Date
JP2016517960A JP2016517960A (ja) 2016-06-20
JP2016517960A5 true JP2016517960A5 (https=) 2017-03-30
JP6402173B2 JP6402173B2 (ja) 2018-10-10

Family

ID=50686216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506682A Expired - Fee Related JP6402173B2 (ja) 2013-04-05 2014-04-07 Ｈｅｒ３の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法

Country Status (6)

Country Link
US (1) US20160041171A1 (https=)
EP (1) EP2981828A1 (https=)
JP (1) JP6402173B2 (https=)
CN (1) CN105264382A (https=)
CA (1) CA2908515A1 (https=)
WO (1) WO2014165855A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
US20190041389A1 (en) * 2015-02-13 2019-02-07 The University Of Queensland Methods for classifying tumors and uses therefor
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
CN108780089B (zh) * 2016-03-15 2020-09-08 美国控股实验室公司 评估细胞间的蛋白质相互作用的方法
CN109789204A (zh) * 2016-05-31 2019-05-21 雀巢产品技术援助有限公司 基于her2和her3通路亚型选择乳癌患者药物疗法的方法
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus B.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
KR20180117529A (ko) * 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
WO2018212656A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
US20210239702A1 (en) * 2018-06-14 2021-08-05 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU636110B2 (en) 1988-06-08 1993-04-22 Nichols Institute Diagnostics Assays utilizing sensitizer-induced production of detectable signal
US4997928A (en) 1988-09-15 1991-03-05 E. I. Du Pont De Nemours And Company Fluorescent reagents for the preparation of 5'-tagged oligonucleotides
US5654442A (en) 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0484027B1 (en) 1990-11-02 1996-12-18 Zeneca Limited Polysubstituted phthalocyanines
JP2758730B2 (ja) 1991-04-25 1998-05-28 三菱電機株式会社 放電励起パルスレーザ発振装置
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ES2268684T3 (es) 1992-04-10 2007-03-16 Dana-Farber Cancer Institute, Inc. Inmunodeteccion de fosfoproteina especifica al estado de activacion.
ATE162892T1 (de) 1992-07-31 1998-02-15 Behringwerke Ag Photoaktivierbare chemiluminizierende matrices
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5986076A (en) 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US6001673A (en) 1999-02-11 1999-12-14 Ericsson Inc. Methods for packaging integrated circuit devices including cavities adjacent active regions
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
US6191278B1 (en) 1999-11-03 2001-02-20 Pe Corporation Water-soluble rhodamine dyes and conjugates thereof
US6346384B1 (en) 2000-03-27 2002-02-12 Dade Behring Inc. Real-time monitoring of PCR using LOCI
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
WO2001084157A2 (en) 2000-05-04 2001-11-08 Dade Behring Marburg Gmbh Compositions for detection of multiple analytes
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
PL373962A1 (en) 2001-05-21 2005-09-19 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
WO2003051669A1 (en) 2001-12-18 2003-06-26 Aclara Biosciences, Inc. Photoactivation device and method
US6949347B2 (en) 2002-03-05 2005-09-27 Aclara Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
JP4443407B2 (ja) 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
CA2521077A1 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers
WO2009068423A2 (en) * 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172984A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
JP6186575B2 (ja) * 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
CN102492039B (zh) * 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗

Similar Documents

Publication Publication Date Title
JP2016517960A5 (https=)
Takenaka et al. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta‐analysis
Parseghian et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
JP2012515226A5 (https=)
Mar et al. Targeting HER2 in the treatment of non-small cell lung cancer
Connell et al. Activating HER2 mutations as emerging targets in multiple solid cancers
ES2687783T3 (es) Biomarcadores de cáncer y usos de los mismos
JP6055764B2 (ja) 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
JP2014074724A5 (https=)
CA2749846A1 (en) Methods of determining patient response by measurement of her-3
JP2019022529A (ja) 細胞全体でのアッセイおよび方法
Oh et al. Clinical activity of pan-HER inhibitors against HER2-mutant lung adenocarcinoma
JP2010510784A5 (https=)
KR20130055647A (ko) 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
KR20130091746A (ko) 췌장암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
Lee et al. Detection of ERBB2 (HER2) gene amplification events in cell-free DNA and response to anti-HER2 agents in a large asian cancer patient cohort
Boylan et al. Characterization of the anti‐factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence‐based immunoassay
JP2018523105A5 (https=)
JP2016014671A (ja) 抗癌治療への応答可能性の増大した患者を同定する方法
Pastor-Barriuso et al. Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study
JP2016515141A5 (https=)
Myer et al. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer
Leite et al. Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis
JP2019519772A (ja) Ｈｅｒ２及びｈｅｒ３の経路サブタイピングに基づく乳癌患者の薬物療法の選択方法
Subramaniam Precision medicine & PET/CT: challenges and implementation